116 related articles for article (PubMed ID: 10402249)
1. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
Mensah-Osman EJ; Al-Katib AM; Mohammad RM
Clin Cancer Res; 2003 Nov; 9(15):5794-7. PubMed ID: 14654565
[TBL] [Abstract][Full Text] [Related]
6. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
[TBL] [Abstract][Full Text] [Related]
7. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
[TBL] [Abstract][Full Text] [Related]
8. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
9. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
[TBL] [Abstract][Full Text] [Related]
11. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
[TBL] [Abstract][Full Text] [Related]
16. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.
Nabha SM; Wall NR; Mohammad RM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2000 Jun; 11(5):385-92. PubMed ID: 10912955
[TBL] [Abstract][Full Text] [Related]
17. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Mohammad RM; Li Y; Mohamed AN; Pettit GR; Adsay V; Vaitkevicius VK; Al-Katib AM; Sarkar FH
Pancreas; 1999 Nov; 19(4):353-61. PubMed ID: 10547195
[TBL] [Abstract][Full Text] [Related]
18. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
20. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Ditzel Santos D; Ho AW; Tournilhac O; Hatjiharissi E; Leleu X; Xu L; Tassone P; Neri P; Hunter ZR; Chemaly MA; Branagan AR; Manning RJ; Patterson CJ; Moreau AS; Ciccarelli B; Adamia S; Kriangkum J; Kutok JL; Tai YT; Zhang J; Pilarski LM; Anderson KC; Munshi N; Treon SP
Exp Hematol; 2007 Sep; 35(9):1366-75. PubMed ID: 17761288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
